Pulmonary Hypertension in Parenchymal Lung Disease

被引：5
|
作者：
Tsangaris, Iraklis [1 ,2 ]
Tsaknis, Georgios [1 ,2 ]
Anthi, Anastasia [1 ,2 ]
Orfanos, Stylianos E. [2 ]
机构：
[1] Univ Athens, Attikon Univ Hosp, Sch Med, Dept Crit Care 2, 1 Rimini St, Athens GR-12462, Greece
[2] Univ Athens, Attikon Univ Hosp, Sch Med, Pulm Hypertens Clin, Athens GR-12462, Greece
来源：
PULMONARY MEDICINE | 2012年 / 2012卷
关键词：
D O I：
10.1155/2012/684781
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Idiopathic pulmonary arterial hypertension (IPAH) has been extensively investigated, although it represents a less common form of the pulmonary hypertension (PH) family, as shown by international registries. Interestingly, in types of PH that are encountered in parenchymal lung diseases such as interstitial lung diseases (ILDs), chronic obstructive pulmonary disease (COPD), and many other diffuse parenchymal lung diseases, some of which are very common, the available data is limited. In this paper, we try to browse in the latest available data regarding the occurrence, pathogenesis, and treatment of PH in chronic parenchymal lung diseases.
引用
收藏
页数：14
相关论文
共 50 条
  • [1] Pulmonary Hypertension in Parenchymal Lung Disease
    Ruggiero, Rosechelle M.
    Bartolome, Sonja
    Torres, Fernando
    [J]. HEART FAILURE CLINICS, 2012, 8 (03) : 461 - +
  • [2] Pulmonary hypertension associated with parenchymal lung disease
    Chandy, George
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2010, 26 : 21B - 23B
  • [3] Pathophysiology of Pulmonary Hypertension in Chronic Parenchymal Lung Disease
    Singh, Inderjit
    Ma, Kevin Cong
    Berlin, David Adam
    [J]. AMERICAN JOURNAL OF MEDICINE, 2016, 129 (04): : 366 - 371
  • [4] Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases
    Shlobin, Oksana A.
    Brown, A. Whitney
    Nathan, Steven D.
    [J]. CHEST, 2017, 151 (01) : 204 - 214
  • [5] A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease
    Madden, B. P.
    Allenby, M.
    Loke, T-K.
    Sheth, A.
    [J]. THORAX, 2006, 61 : II65 - II65
  • [6] A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease
    Madden, BP
    Allenby, M
    Loke, TK
    Sheth, A
    [J]. VASCULAR PHARMACOLOGY, 2006, 44 (05) : 372 - 376
  • [7] Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease
    Tan, RT
    Kuzo, R
    Goodman, LR
    Siegel, R
    Haasler, GB
    Presberg, KW
    [J]. CHEST, 1998, 113 (05) : 1250 - 1256
  • [8] Correlation between the severity of pulmonary hypertension and vascular remodeling in chronic obstructive pulmonary disease and diffuse parenchymal lung disease awaiting lung transplantation
    Grignola Rial, J.
    Domingo, E.
    Zavala, G.
    Lopez Messeguer, M.
    Berastegui, C.
    Roman, A.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 176 - 176
  • [9] Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease A Focus on Right Ventricular (Dys) Function
    Tseng, Steve
    Stanziola, Anna Agnese
    Sultan, Samir
    Henry, Kyle
    Saggar, Rajeev
    Saggar, Rajan
    [J]. HEART FAILURE CLINICS, 2018, 14 (03) : 403 - +
  • [10] Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease
    Baughman, Robert
    Culver, Daniel
    Cordova, Francis
    Padilla, Maria
    Gibson, Kevin
    Lower, Elyse
    Engel, Peter
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40
12345